Norambuena A, Sagar VK, Wang Z, Raut P, Feng Z, Wallrabe H, Pardo E, Kim T, Alam SR, Hu S, Periasamy A, Bloom GS. Disrupted mitochondrial response to nutrients is a presymptomatic event in the cortex of the APPSAA knock-in mouse model of Alzheimer disease. 2024 Feb 04 10.1101/2024.02.02.578668 (version 1) bioRxiv.
Recommends
Please login to recommend the paper.
Comments
Max Planck Institute for Biological Intelligence
Defects in proteostasis and the accumulation of toxic misfolded proteins, as well as mitochondrial dysfunction and a neuroenergetic crisis are intimately linked to each other in the pathogenesis of neurodegenerative diseases. This preprint tries to shed light on the disease progression in Alzheimer’s disease by analyzing mitochondrial function in vivo by NAD/NAD(P)H lifetime imaging and oxygen measurements in the cortices of young APPSAA mice. While no steady-state differences are evident, the mTORC1-driven activation of respiration in response to branched amino acids is impaired in the AD model mice.
While this finding is intriguing, by nature of the minimally invasive, marker-less imaging techniques, the authors cannot distinguish the contribution of different cell types to this response. The mTORC1 signaling cascade is functional in neurons and certainly regulates aspects of mitochondrial function, but the downstream effects are not always similar to other cell types, e.g., there is no induction of autophagy in response to mTORC1 inhibition in neurons (Maday and Holzbaur, 2016). I believe it is too early to claim a causal relationship between APP mutations/GSK3β/mTORC1/mitochondrial dysfunction in neurons in AD, given the challenges in translating in vitro mechanistical analyses in isolated cell types to the complex cellular environments and interactions in vivo.
References:
Maday S, Holzbaur EL. Compartment-Specific Regulation of Autophagy in Primary Neurons. J Neurosci. 2016 Jun 1;36(22):5933-45. PubMed.
View all comments by Angelika HarbauerUniversity of Kansas
I’d like to commend the authors on the technical sophistication of the work, for considering the possibility that mitochondria and energy-related metabolism are relevant to AD, and for offering a generally unique and innovative hypothesis.
The authors report in a mouse model that is engineered to contain a mutated APP under its endogenous promoter, changes in energy and cell-growth related metabolism that manifest prior to plaque deposition. This is consistent with reports from other investigators that, in other mouse models with mutant APP, energy metabolism-related changes substantially precede plaque deposition (Reddy et al, 2004).
The current paper speculates that Aβ oligomers are potentially responsible for this study’s observed metabolism changes, which I expect would be the favored hypothesis of those who believe AD is a primary disorder of Aβ oligomers.
The data in this manuscript are also pertinent to, and potentially consistent with, other data that emphasize functional links between APP and mitochondria, which seem to exist even in the absence of classic APP processing to Aβ (Pope et al., 2021).
References:
Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, Jung Y, Yau V, Searles R, Mori M, Quinn J. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet. 2004 Jun 15;13(12):1225-40. PubMed.
Pope CA, Wilkins HM, Swerdlow RH, Wolfe MS. Mutations in the Amyloid-β Protein Precursor Reduce Mitochondrial Function and Alter Gene Expression Independent of 42-Residue Amyloid-β Peptide. J Alzheimers Dis. 2021;83(3):1039-1049. PubMed.
View all comments by Russell SwerdlowRIKEN Center for Brain Science
Norambuena and colleagues used an APPSAA/AppNL-G-I knock-in mouse model of AD to demonstrate mitochondrial dysfunction in the very early stage of AD development. It is hard to understand why the authors used a copy model of our AppNL-G-F and other knock-in lines (Saito et al., 2014; Watamura et al., 2022), which are being used by more than 800 groups worldwide (Saido, Alzheimer's Research Guide: Animal Models for Understanding Mechanisms and Medications, 2024, Elsevier, in press).
Because more than 200 papers using our knock-in mouse lines have been published and because there will be many more, one can make comparisons with past and future reports by using our models. Also, it is sometimes important to utilize the AppNL or ApphAb lines as a negative control.
References:
Saito T, Matsuba Y, Mihira N, Takano J, Nilsson P, Itohara S, Iwata N, Saido TC. Single App knock-in mouse models of Alzheimer's disease. Nat Neurosci. 2014 May;17(5):661-3. Epub 2014 Apr 13 PubMed.
Watamura N, Sato K, Shiihashi G, Iwasaki A, Kamano N, Takahashi M, Sekiguchi M, Mihira N, Fujioka R, Nagata K, Hashimoto S, Saito T, Ohshima T, Saido TC, Sasaguri H. An isogenic panel of App knock-in mouse models: Profiling β-secretase inhibition and endosomal abnormalities. Sci Adv. 2022 Jun 10;8(23):eabm6155. Epub 2022 Jun 8 PubMed.
View all comments by Takaomi SaidoUniversity of Virginia
University of Virginia
We are grateful for the comments that Alzforum readers made to our bioRxiv preprint. Brain hypometabolism is one the earliest biomarkers in AD pathogenesis, but the underlying mechanisms have been difficult to unravel. Previous work by our lab unveiled a novel form of communication between lysosomes and mitochondria, a signaling pathway we named NiMA, for Nutrient-induced Mitochondrial Activity. NiMA involves activation of the mechanistic target of rapamycin complex 1 (mTORC1) by insulin or the amino acids arginine and leucine to induce mitochondrial respiration within minutes in the absence of mitochondrial biogenesis (Norambuena et al., 2018, 2024). Importantly, NiMA was found to be blocked in cultured neurons by soluble Aβ oligomers (AβOs), which activate mTORC1 at the plasma membrane (Norambuena et al., 2017, 2018) and simultaneously inhibit lysosomal mTORC1 (Norambuena et al., 2022). The current bioRxiv paper, which is under peer review, describes NiMA inhibition in vivo in the brains of an APP knock-in, AD mouse model.
Importantly, we found that NiMA disruption in vivo begins when AβOs are reportedly first detectable in brain, CSF, and plasma, more than a year before any other pathophysiological features are evident in the heterozygous APPSAA/+ mice used for the study. We used these mice simply because they accumulate AβOs sufficiently fast to produce a phenotype, not to argue that NiMA inhibition in vivo requires amyloidogenic APP mutations.
We agree with Angelika Harbauer that this body of work “cannot distinguish the contribution of different cell types to this response,” but it does provide strong evidence that NiMA inhibition does occur in vivo in conditions mimicking a very early stage of AD pathogenesis.
We also want to emphasize that NiMA apparently occurs independently of well-known mTORC1-regulated substrates (Norambuena et al., 2018) and processes such as autophagy (unpublished results).
References:
Norambuena A, Wallrabe H, Cao R, Wang DB, Silva A, Svindrych Z, Periasamy A, Hu S, Tanzi RE, Kim DY, Bloom GS. A novel lysosome-to-mitochondria signaling pathway disrupted by amyloid-β oligomers. EMBO J. 2018 Nov 15;37(22) Epub 2018 Oct 22 PubMed.
Norambuena A, Sagar VK, Wang Z, Raut P, Feng Z, Wallrabe H, Pardo E, Kim T, Alam SR, Hu S, Periasamy A, Bloom GS. Disrupted mitochondrial response to nutrients is a presymptomatic event in the cortex of the APP SAA knock-in mouse model of Alzheimer's disease. bioRxiv. 2024 Feb 4; PubMed.
Norambuena A, Wallrabe H, McMahon L, Silva A, Swanson E, Khan SS, Baerthlein D, Kodis E, Oddo S, Mandell JW, Bloom GS. mTOR and neuronal cell cycle reentry: How impaired brain insulin signaling promotes Alzheimer's disease. Alzheimers Dement. 2017 Feb;13(2):152-167. Epub 2016 Sep 29 PubMed.
Norambuena A, Sun X, Wallrabe H, Cao R, Sun N, Pardo E, Shivange N, Wang DB, Post LA, Ferris HA, Hu S, Periasamy A, Bloom GS. SOD1 mediates lysosome-to-mitochondria communication and its dysregulation by amyloid-β oligomers. Neurobiol Dis. 2022 Jul;169:105737. Epub 2022 Apr 20 PubMed.
View all comments by George BloomUniversity of Leeds
The original paper on the App-SAA knock-in mouse model of Alzheimer’s disease (JAX: 034711) reported that FDG-PET uptake, a surrogate for glucose utilization in brain, revealed cortical hypermetabolism across the studied lifespan of 5-20 months in homozygous App-SAA mice (Fig. 6b, Xia et al., 2022), which Xia et al. contrasted with the hypometabolism reported in the later phase of AD. Heterozygous App-SAA mice were not tested.
The preprint's discussion starts off by mentioning that brain hypometabolism is one of the earliest signs of AD, but the cortical hypermetabolism of homozygous App-SAA mice isn't mentioned.
Can the finding of a disrupted mitochondrial response in heterozygous App-SAA mice help explain the cortical hypermetabolism of homozygous App-SAA mice?
In contrast with App-SAA homozygotes, App-NL-G-F homozygotes do exhibit cerebral glucose hypometabolism (Armstrong et al., 2024).
References:
Xia D, Lianoglou S, Sandmann T, Calvert M, Suh JH, Thomsen E, Dugas J, Pizzo ME, DeVos SL, Earr TK, Lin CC, Davis S, Ha C, Leung AW, Nguyen H, Chau R, Yulyaningsih E, Lopez I, Solanoy H, Masoud ST, Liang CC, Lin K, Astarita G, Khoury N, Zuchero JY, Thorne RG, Shen K, Miller S, Palop JJ, Garceau D, Sasner M, Whitesell JD, Harris JA, Hummel S, Gnörich J, Wind K, Kunze L, Zatcepin A, Brendel M, Willem M, Haass C, Barnett D, Zimmer TS, Orr AG, Scearce-Levie K, Lewcock JW, Di Paolo G, Sanchez PE. Novel App knock-in mouse model shows key features of amyloid pathology and reveals profound metabolic dysregulation of microglia. Mol Neurodegener. 2022 Jun 11;17(1):41. PubMed.
Armstrong P, Güngör H, Anongjanya P, Tweedy C, Parkin E, Johnston J, Carr IM, Dawson N, Clapcote SJ. Protective effect of PDE4B subtype-specific inhibition in an App knock-in mouse model for Alzheimer's disease. Neuropsychopharmacology. 2024 Sep;49(10):1559-1568. Epub 2024 Mar 23 PubMed.
Make a Comment
To make a comment you must login or register.